Biogen Acquires RayThera to Boost Immunology Pipeline
BIIB sits 64% above its 52-week low of $121.05.
Summary
Biogen announced an agreement to acquire RayThera Inc., a move designed to expand its immunology pipeline. This acquisition continues Biogen's recent strategic focus on M&A and pipeline growth, following the $5.3 billion Apellis Pharmaceuticals acquisition and several licensing deals earlier this year. The deal strengthens Biogen's presence in the immunology therapeutic area, adding new assets to its development portfolio.
At the time of this announcement, BIIB was trading at $197.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.3B. The 52-week trading range was $121.05 to $205.97. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.